reboxetine has been researched along with Innate Inflammatory Response in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caso, JR; García-Bueno, B; González-Prieto, M; Gutiérrez, IL; Leza, JC; Madrigal, JLM | 1 |
| Arolt, V; Cerovecki, A; Dehning, S; Douhe, A; Goldstein-Müller, B; Hetzel, G; Kleindienst, N; Maino, K; Möller, HJ; Müller, N; Riedel, M; Schwarz, MJ; Spellmann, I | 1 |
1 trial(s) available for reboxetine and Innate Inflammatory Response
| Article | Year |
|---|---|
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Anxiety Agents; Antidepressive Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Depressive Disorder; Dinoprostone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inflammation; Interleukin-6; Lorazepam; Male; Middle Aged; Morpholines; Patient Dropouts; Pilot Projects; Psychological Tests; Pyrazoles; Reboxetine; Serotonin; Severity of Illness Index; Sulfonamides | 2006 |
1 other study(ies) available for reboxetine and Innate Inflammatory Response
| Article | Year |
|---|---|
Reboxetine Treatment Reduces Neuroinflammation and Neurodegeneration in the 5xFAD Mouse Model of Alzheimer's Disease: Role of CCL2.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Axons; Biomarkers; Chemokine CCL2; Cyclooxygenase 2; Disease Models, Animal; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Inflammation; Memory Disorders; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Nerve Degeneration; Reboxetine | 2019 |